US64125C1099
US64125C1099
Neurocrine Biosciences, Inc.
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 14.48B EUR | 17.12B EUR | 13.25B EUR | 14.2B EUR |
Enterprise Value | 14.43B EUR | 17.19B EUR | 13.39B EUR | 13.9B EUR |
Valuation Multiples | ||||
Trailing P/E | 20.89x | 24.27x | 19.82x | 30.16x |
Forward P/E | 11.99x | -- | -- | -- |
Price to Sales | 4.29x | 5.08x | 4.27x | 6.21x |
Price to Book | 3.92x | 4.64x | 3.89x | 4.36x |
EV/Revenue | 4.28x | 5.1x | 4.32x | 6.08x |
EV/EBITDA | 15.8x | 20.99x | 16.86x | 21.01x |
Price to FCF (P/FCF) | 22.69x | 19.67x | 15.94x | 20.44x |
EV/FCF | 22.61x | 19.75x | 16.11x | 20.01x |
FCF Yield | 4.41% | 5.08% | 6.27% | 4.89% |